Advances in epigenetic biomarker research in colorectal cancer

doi:10.3748/wjg.v20.i15.4276

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 15

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7318)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

655

WORD

260

HTML

4482

Tables (1-5)

117

Sum=5514

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

858

Download

946

Sum=1804

Apr 21, 2014 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 21, 2014; 20(15): 4276-4287
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4276

Table 1 Biomarkers of DNA methylation in blood of colorectal cancer patients, n (%)

Markers	Sensitivity	Specificity	Ref.
APC	3 (6)	0 (100)	[20]
hMLH1	21 (43)	1 (98)	[20]
HLTF	17 (34)	1 (98)	[20]
HLTF	22 (21)	0 (100)	[21]
ALX4	25 (83)	9 (70)	[22]
TMEFF2	87 (65)	56 (69)	[23]
NGFR	68 (51)	29 (84)	[23]
9-Sep	92 (69)	25 (86)	[23]
9-Sep	90 (72)	19 (90)	[24]
9-Sep	24 (72)	3 (90)	[25]
9-Sep	18 (60)	5 (89)	[26]
9-Sep	45 (90)	11 (89)	[27]
NEUROG1	14 (52)-stage I 45 (64)-stage II	4 (91)	[28]
SFRP2	113 (67)	4 (94)	[29]
CDKN2A/P16	12 (71)	0 (100)	[30]
RUNX3	11 (65)	0 (100)	[30]
TPEF/HPP1	13 (13)	0 (100)	[21]

APC: Adenomatosis polyposis coli; hMLH1: Homo mutL homolog 1; HLTF: Helicase-like transcription factor; ALX4: ALX homeobox 4; TMEFF2: Transmembrane protein with EGF-like and two follistatin-like domains 2; NGFR: Nerve growth factor receptor; NEUROG1: Neurogenin 1; SFRP2: Secreted frizzled-related protein 2; CDKN2A: Cyclin-dependent kinase inhibitor 2A; RUNX3: Runt-related transcription factor 3; HPP1: Hyperpigmentation, progressive, 1; TPEF: Transmembrane protein endothalial factor.

Table 2 Biomarkers of DNA methylation in the stool of colorectal cancer patients

Markers	Sample	Sensitivity	Specificity	Ref.
AGTR1/WNT2/ SLIT2/VIM/SEPT9	214 CRC	20%-78%	86%-100%	[33]
	25 IBD
	39 controls
Vimentin/EYA4/ BMP3/NDRG4	CRC	67%-100%	89%	[34]
ESR1	19 CRC	65%	81%	[35]
ESR1	38 controls		81%	[35]
SLIT2	60 CRC		100%	[36]
	32 IBD associated CRC
	20 HR-IBD	25%
	65 LR-IBD
	28 controls
PHACTR3	64 CRC	66%	100%	[37]
	71 A	32%
	34 controls
TFPI2	60 CRC	68.3%	100%	[38]
	20 A
	30 controls
CNRIP1/FBN/INA/ MAL/SNCA/SPG20	78 CRC	65%-94%	95%-100%	[39]
	61 A	35%-91%
	48 controls
SPG20	9 CRC	67%	Unknown	[40]
MAL/CDKN2A/ MGMT	69 CRC	55.1%-78.3%	96.2%-100%	[41]
	24 A	37.5%-58.3%
	19 HP	10.5%-26.3%
	24 controls
3OST2	21 CRC	72.7%	90%	[42]
ITGA4/SFRP2/p16	30 CRC	70%	96.8%	[43]
	25 A	72%
	21 controls
RARB2/p16/ INK4a/MGMT/APC	26 CRC	62%	100%	[44]
	20 A	40%
	16 IBD	13%
	20 controls
RASSF1/SFRP2	84 CRC	75%	89%	[45]
	27 advanced A	44%
	29 non-advanced A	28%
	12 HP	25%
	4 IC	25%
	2 UC	100%
	113 controls
OSMR	69 CRC	38%	95%	[46]
OSMR	81 controls		95%	[46]
Vimentin	22 CRC	41%	95%	[47]
	20 advanced A	45%
	38 controls
MGMT/hMLH1/ Vimentin	60 CRC	75%	87%	[48]
	22 advanced A	46%
	30 non-advanced A	70%
	37 controls
ITGA4	13 A	69%	79%	[49]
NDRG4	75 CRC	53%-61%	93%-100%	[50]
NDRG4	75 controls		93%-100%	[50]
GATA4	75 CRC	51%-71%	84%-93%	[51]
GATA4	75 controls		84%-93%	[51]
TFPI2	26 CRC	76%-89%	79%-93%	[17]
TFPI2	45 controls		79%-93%	[17]
SFRP2	69 CRC	87.0%	93%	[52]
	34 A	61.8%
	26 HP	42.3%
	30 controls
SFRP2	13 A	46%	100%	[53]
	6 HP	33%
	6 controls
Vimentin	103 A	46%	84%	[54]
Vimentin	75 controls		84%	[54]
Vimentin/DIA	42 CRC	86%	73%	[55]
Vimentin/DIA	241 controls		73%	[55]
CDKN2A/p16/ MSI/long DNA	25 CRC	64%	95%	[56]
CDKN2A/p16/ MSI/long DNA	20 controls		95%	[56]
SFRP2	52 CRC	94%	93%	[57]
	10 advanced A	70%
	11:00 AM	36%
	8 HP	38%
	6 UC	17%
	24 controls
SFRP2/HPP1/ MGMT	52 CRC	96%	96%	[58]
	10 advanced A	80%
	11 non-advanced A	64%
	8 HP	38%
	6 UC	17%
	24 controls
Vimentin/DIA	40 CRC	88%	82%	[59]
Vimentin/DIA	122 controls		82%	[59]
ATM/APC/ MGMT/hMLH1/ HLTF/SFRP2/GSTP1	20 CRC	75%	90%	[60]
	30 A	68%
	30 controls
	241 controls
Vimentin	74 CRC	72%	89%	[61]
	62 A	84%
	70 controls
Vimentin	94 CRC	46%	90%	[62]
Vimentin	198 controls		90%	[62]
HIC1	26 CRC	42%	98%	[63]
	13 A	31%
	9 HP	0%
	41 controls
CDKN2A/MGMT/ hMLH1	29 A	55%	72%	[64]
	10 HP	40%
	25 controls
ATM/APC/ MGMT/hMLH1/ HLTF	20 CRC	70%	100%	[65]
ATM/APC/ MGMT/hMLH1/ HLTF	20 controls		100%	[65]
SFRP2	23 CRC	77%-90%	77%	[66]
	26 controls
	10 HP	40%
	25 controls

A: Adenoma; HP: Hyperplastic polyp; HR: High risk; LR: Low risk; IBD: Inflammatory bowel disease; IC: Ischemic colitis; UC: Ulcerative colitis; CRC: Colorectal cancer; AGTR1: Angiotensin II receptor, type 1; WNT2: Wingless-type MMTV integration site family member 2; SLIT2: Slit homolog 2; VIM: Vimentin; EYA4: Eyes absent homolog 4; BMP3: Bone morphogenetic protein 3; NDRG4: NDRG family member 4; ESR1: Estrogen receptor 1; PHACTR3: Phosphatase and actin regulator 3; TFPI2: Tissue factor pathway inhibitor 2; CNRIP1: Cannabinoid receptor interacting protein 1; FBN: Fibrillin; INA: Internexin neuronal intermediate filament protein, alpha; MAL: Mal, T-cell differentiation protein; SNCA: Synuclein, alpha; SPG20: Spastic paraplegia 20; MGMT: O-6-methylguanine-DNA methyltransferase; 3OST2: Heparan sulfate (glucosamine) 3-O-sulfotransferase 2; ITGA4: Integrin, alpha 4; RARB2: Retinoic acid receptor, beta 2; RASSF1: Ras association (RalGDS/AF-6) domain family member 1; OSMR: Oncostatin M receptor; GATA4: GATA binding protein 4; TFPI2: Tissue factor pathway inhibitor 2; CDKN2A: Cyclin-dependent kinase inhibitor 2; ADIA: DNA integrity assay; MSI: Microsatellite instability; GSTP1: Glutathione S-transferase pi 1; HIC1: Hypermethylated in cancer 1; ATM: Ataxia telangiectasia mutated; APC: Adenomatosis polyposis coli; hMLH1: Homo mutL homolog 1; HLTF: Helicase-like transcription factor; SFRP2: Secreted frizzled-related protein 2.

Table 3 MicroRNAs found in colorectal cancer but not in normal tissue

Up-regulated	miR-7, miR-17, miR-18a, miR-19a, miR-20a, miR-20, miR-21, miR-25, miR-29a, miR-29b, miR-32, miR-33a, miR-34a, miR-34b, miR-92a, miR-93, miR-95, miR-96, miR-101, miR-106a, miR-106b, miR-130, miR-135a, miR-135b, miR-181b, miR-182, miR-183, miR-191, miR-200c, miR-203, miR-222, miR-223, miR-224, miR-378, miR-155
Down-regulated	miR-30a, miR-30c, miR-34a, miR-125a, miR-126, miR-133a, miR-133b, miR-143, miR-145, miR-191, miR-192, miR-195, miR-215, miR-342, miR-497, miR-375, miR-378, miR-1, miR-9, miR-129, miR-137, miR-139

The underlined genes miR-34a, miR-191 and miR-378 were reported to be up-regulated in some studies[71-73] and down-regulated in others[74-76].

Table 4 MicroRNA biomarkers in the blood and stool of colorectal cancer patients

Markers	Sample	Sensitivity	Specificity	Ref.
Blood
miR-21	186 CRC	76.8%-82.8%	81.1%-90.6%	[77]
	43 A	91.9%	81.1%
	53 controls
miR-601/ miR-760	90 CRC	83.3%	69.1%	[78]
	48 AA	72.1%	62.1%
	58 controls
miR-21	30 CRC	90.0%	90.0%	[79]
miR-21	30 controls			[79]
miR-29a	258 plasma sample	75.0%	75.0%	[80]
miR-141	102 CRC	77.1%-90.9%	77.1%-89.7%	[81]
miR-92a	120 CRC	84.0%	71.2%	[82]
	37 AA	64.9%	81.4%
	59 controls
miR-29a	120 CRC	69.0%	89.1%	[82]
	37 AA	62.2%	84.70%
	59 controls
miR-221	103 CRC	86.0%	41.0%	[83]
miR-221	37 controls			[83]
miR-17-3P	90 CRC	64.0%	70.0%	[84]
miR-17-3P	50 controls			[84]
miR-92a	90 CRC	89.0%	70.0%	[84]
miR-92a	50 controls			[84]
Stool
miR-21	88 CRC	55.7%	73.3%	[85]
	57 polyps	43.9%
	101 controls
miR-92a	88 CRC	71.6%	73.3%	[85]
	57 polyps	56.1%
	101 controls
miR-144*	75 CRC	74.0%	87.0%	[86]
miR 17-92 cluster	197 CRC	69.5%	81.5%	[87]
miR 17-92 cluster	119 controls		81.5%	[87]
miR-135	197CRC	46.2%	95.0%	[87]
miR-135	119 controls		95.0%	[87]
miR-21	197 CRC	14.7%	91.6%	[87]
miR-21	119controls		91.6%	[87]
miR-92a	59 CRC	50.0%	80.0%	[88]
miR-92a	74 controls		80.0%	[88]
miR-21	59 CRC	50.0%	83.0%	[88]
miR-21	74 controls		83.0%	[88]

A: Adenoma; CRC: Colorectal cancer.

Table 5 Relationship between microRNAs and screening, diagnosis and prognosis in colorectal cancer

Screening	miR-17-92, miR-20a, miR-21, miR-92, miR-96, miR-106a, miR-135, miR-144, miR-203, miR-326, miR-181b, miR-601, miR-760
Diagnosis	miR-133b, miR-143, miR-145, miR-17-92, miR-18a, miR-20a, miR-21, miR-31, miR-92, miR-96, miR-135b, miR-183
Prognosis	miR-18a, miR-21, miR-20a, miR-31, miR-143, miR-145, miR-155, miR-181b, miR-200c, miR-203, miR-106a, miR-17-92, miR-135a, miR-335, miR-206, miR-10b, miR-146a/b, let7a/b
Treatment	miR-21, miR-17, miR-215, miR-125b, miR-137, miR-143, miR-145, miR-192, miR-622, miR-630

Citation: Wang X, Kuang YY, Hu XT. Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol 2014; 20(15): 4276-4287
URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4276.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i15.4276